lunes, 4 de agosto de 2014

Metastatic Colorectal Cancer Treatmen... [Clin Colorectal Cancer. 2014] - PubMed - NCBI

2014 Jun 23. pii: S1533-0028(14)00057-7. doi: 10.1016/j.clcc.2014.05.001. [Epub ahead of print]

Metastatic Colorectal Cancer Treatment Patterns According to Kirsten Rat Sarcoma Viral Oncogene Homolog Genotype in U.S. Community-Based Oncology Practices.

Landsman-Blumberg PB1, Carter GC2, Johnson BH1, Sedgley R1, Nicol SJ3, Li L3, Shankaran V4.

Author information

Abstract

INTRODUCTION:

In 2008, the National Comprehensive Cancer Network guidelines were revised in light of the identification of the Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) gene as a biomarker of nonresponse to epidermal growth factor receptor inhibitors. This study sought to describe and compare real-world treatment patterns of metastatic colorectal cancer (mCRC) according to KRAS genotype in community-based oncology practices in the United States.

MATERIALS AND METHODS:

Data from the ACORN (ACORN LLC, Memphis, TN) electronic medical record data warehouse, containing data of approximately 180,000 patients from 12 oncology practices across the United States were used. Records of adult patients with mCRC who had undergone KRAS testing between January 2008 and December 2011 were evaluated. Patient demographic characteristics, KRAS genotype, and treatment patterns were identified and compared.

RESULTS:

Six hundred forty-eight mCRC patients who were tested for KRAS were identified. Of these, 48.1% had wild type (WT), 42.3% mutant, and 9.6% unknown genotypes. Most patients (72.1%) were tested in 2009 or later, after the guideline revision. Bevacizumab-containing combinations were the most common first-line regimens in KRAS mutant and WT patients. Approximately 90% of patients received at least 1 line of therapy, however, WT patients received significantly more lines of therapy than KRAS mutant patients (2.6 ± 1.5 vs. 2.1 ± 1.2; P < .001).

CONCLUSIONS:

KRAS WT and mutant genotypes had similar first-line regimens; however, WT patients received more lines of therapy. Although there does not appear to be a lag between changes in guidelines and treatment practice, professional and government organizations must keep up with the changing science and disseminate this information to oncologists in a timely manner.